Although our data suggest that MMR defects represent a minor tumorigenic pathway in the development of UUC, the high frequency of MSH2/MSH6 loss in MMR-defective tumors should caution clinicians to obtain an individual and a family history of cancer in patients with carcinomas of the renal pelvis and the ureter. The gene discussed is MSH2; the disease is cancer.